173TiP PECan study, imaging PD-L1 in cancer: A tool for measuring response to immunotherapy?
This study is now open to recruitment with reporting expected late 2020.Clinical trial identificationUK IRAS ID 256684.Legal entity responsible for the studyKing's College London and Guy's and St Thomas' NHS Foundation Trust.FundingDepartment of Cancer Imaging, King's College London, UK with funding from NanoMab Technology Limited, China.DisclosureG. Chand: Advisory / Consultancy, Shareholder / Stockholder / Stock options: NanoMab Technology Limited. H.H. Ting: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: NanoMab Technology Limited. G. Cook: Research grant / Funding (institution): NanoMab Technology Limited. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | China Health | Clinical Trials | Consultancies | CT Scan | Employment | Foundation Trusts | Funding | Grants | Immunotherapy | Legislation | Lung Cancer | Melanoma | Nanotechnology | Non-Small Cell Lung Cancer | Nuclear Medicine | Pecan | Skin Cancer | SPECT | Study